Replacement of streptomycin by ethambutol in the intensive phase of tuberculosis treatment: No effect on compliance

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 1, 1999, Pages 42-46

  Rabarijaona, L ^a   Boisier, Pascal ^a,c   Ratsirahonana, O ^b   Razafinimanana, J ^b   Rakotomanana, F ^a   Ratsitorahina, M ^a   Ramarokoto, H ^a,b   Cauchoix, B ^b   Auregan G ^b  

^a INSTITUT PASTEUR DE MADAGASCAR   (Madagascar)

^b Prog Natl Lutte Antituberculeuse   (Madagascar)

^c HÔPITAL D'INSTRUCTION DES ARMÉES ROBERT PICQUÉ   (France)

Author keywords

Controlled clinical trial; Ethambutol; Madagascar; Pulmonary tuberculosis; Streptomycin; Treatment compliance

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; MADAGASCAR; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHOOL CHILD; TINNITUS; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; CHILD; ETHAMBUTOL; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; STREPTOMYCIN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 0033021969     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Aurégan G, Rakotondramarina D, Razafinimanana J, Ramarokoto H, Ratsirahonana O, Ralamboson M. Le programme national de lutte antituberculeuse (PNLAT) à Madagascar. Arch Inst Pasteur Madagascar 1995; 62: 4-12.
2. Antituberculosis regimens of chemotherapy: Recommendations from the Committee on Treatment of the International Union Against Tuberculosis and Lung Disease. Bull Int Union Tuberc Lung Dis 1988; 63 (2): 60-64.
3. Reichman L B. Compliance in developed nations. Tubercle 1987; 68 (Suppl): 25-29.
4. Fox W. Whither short course chemotherapy? Bull Int Union Tuberc 1981; 56 (3-4): 135-155.
5. Chaulet P. Compliance with antituberculosis chemotherapy in developing countries. Tubercle 1987; 68 (Suppl): 19-24.
6. Chaulet P. Compliance with chemotherapy for tuberculosis. Responsibilities of the Health Ministry and of physicians. 1991; 66 (Suppl 1990/91): 33-36.
7. Murray C J L, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990; 65 (1): 6-26.
8. Commission du Traitement de Union International contre la Tuberculose et les Maladies Respiratoires: Considérations sur les médicaments antituberculeux et recommandations sur les régimes de chimiothérapic. Rev Fr Mal Resp 1976; 4: 157-163.
9. Papillon F H, Chrétien J. Bases théoriques du traitement actuel de la tuberculose. Méd et Hyg 1978; 36: 1526-1532.
10. Boisier P, Rabarijaona L, Rakotomanana F, et al. Comparaison de protocoles thérapeutiques utilisés en routine à Madagascar dans le traitement des tuberculoses pulmonaires a microscopie positive. (Résultats préliminaires). Arch Inst Pasteur Madagascar 1995; 62: 72-76.
11. Chanteau S, Rasolofo V, Ramarokoto H, et al. Anti-tuberculosis drug resistance in Madagascar in 1994-1995. Int J Tuberc Lung Dis 1997; 1: 405-410.
12. Gninafon M, Lambregts van Weezenbeek C S B, Tawo L, Trébucq A. Ethambutol versus streptomycin during the hospitalized intensive phase of tuberculosis treatment in Benin. Tubercle Lung Dis 1995; 76: 373-376.
13. Chum H J, Ilmolelian G, Rieder H L, et al. Impact of the change from an injectable to a fully oral regimen on patient adherence to ambulatory tuberculosis treatement in Dar es Salaam, Tanzania. Tubercle Lung Dis 1995; 76: 286-289.
14. Enarson D, Jentgens H, Oberhoffer M, et al. Tuberculosis guide for high prevalence countries. 2nd ed. Paris: IUATLD, 1991.
15. Jeannin L. Tuberculose pulmonaire et primo infection tuberculeuse. Epidémiologie, diagnostic, évolution, traitement, prévention. Rev Prat 1997; 47: 97-106.